Welcome to our dedicated page for Xenon Pharmaceut SEC filings (Ticker: XENE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing Xenon Pharmaceuticals’ dense biotech disclosures is no small task; a single 10-K can bury crucial details on epilepsy trial progress, cash runway, and royalty obligations deep inside footnotes. If you’ve ever wondered how to locate "Xenon Pharmaceuticals insider trading Form 4 transactions" or confirm the next XEN1101 milestone payment without skimming hundreds of pages, you’re not alone.
Stock Titan solves that problem. Our AI reads every 10-K annual report, 10-Q quarterly earnings report, 8-K material event, and Form 4 insider filing the instant they hit EDGAR and delivers plain-English takeaways. Think of it as "understanding Xenon Pharmaceuticals SEC documents with AI"—R&D burn rates, Phase 3 enrollment updates, or executive stock option grants are surfaced in seconds. Real-time alerts keep you ahead when "Xenon Pharmaceuticals Form 4 insider transactions" post mid-session.
- Xenon Pharmaceuticals quarterly earnings report 10-Q filing with pipeline spend broken down
- Xenon Pharmaceuticals annual report 10-K simplified—risk factors, cash position, dilution tables
- Xenon Pharmaceuticals executive stock transactions Form 4 and related proxy statement executive compensation
- Xenon Pharmaceuticals 8-K material events explained—FDA feedback, trial pauses, public offerings
- Xenon Pharmaceuticals earnings report filing analysis powered by AI
Whether you’re tracking "Xenon Pharmaceuticals insider trading Form 4 transactions real-time" before a data readout or comparing sequential R&D spend, our platform condenses complex biotech language into actionable insights. Save hours, reduce uncertainty, and focus on what matters: the science and the numbers.
Xenon Pharmaceuticals (XENE) reported Q3 2025 results with a net loss of
Operating expenses rose as late-stage programs advanced: R&D was
Pipeline updates: the Phase 3 X‑TOLE2 study in focal onset seizures completed enrollment (380 randomized) with topline data anticipated in early 2026; Phase 3 X‑TOLE3 (FOS) and X‑ACKT (PGTCS) continue. Phase 3 programs in MDD (X‑NOVA2/3) and bipolar depression (X‑CEED) are underway. Early-stage pain candidates include XEN1701 (Nav1.7) and XEN1120 (Kv7) in Phase 1.
Xenon Pharmaceuticals (XENE) furnished an update on its latest results. The company announced financial results for the three and nine months ended September 30, 2025 via a press release attached as Exhibit 99.1. The information under Item 2.02 and the exhibit are furnished, not filed with the SEC.
Xenon also notes it shares material updates through SEC filings, press releases, conference calls, its websites, and official social media channels.
Xenon Pharmaceuticals (XENE)10/15/2025, the officer received a stock option for 225,000 common shares at an exercise price of $41.9, expiring on 10/14/2035. The option vests 25% on October 15, 2026, with the remaining 75% vesting in equal monthly installments over the next three years.
The filing also reports 30,000 restricted share units (RSUs), vesting 25% on each of the first four anniversaries of the grant date, beginning October 15, 2026. The awards are reported as direct ownership.
Xenon Pharmaceuticals (XENE) filed a Form 3 initial ownership report. The reporting person is an officer serving as Chief Financial Officer and indicated no securities are beneficially owned (0) and no derivative securities are held. The stated date of event is 10/15/2025. The filing reflects an individual submission by one reporting person.
Xenon Pharmaceuticals (XENE) appointed Thomas (Tucker) Kelly as Chief Financial Officer, effective October 15, 2025. He becomes the company’s principal financial and accounting officer, bringing prior CFO experience at Deciphera Pharmaceuticals and earlier roles across life sciences finance, banking, and law.
Under his employment terms, Mr. Kelly will receive a $540,000 annual base salary and is eligible for an annual incentive of up to 45% of base salary. He will receive a one-time grant of 225,000 options and 30,000 RSUs under the 2025 Inducement Equity Incentive Plan. Severance terms include up to 18 months of base salary depending on tenure, pro-rated Average Bonus, retirement contribution equivalents for the severance period, and equity vesting and exercisability provisions, with enhanced benefits upon a qualifying termination during a change of control period. Ian Mortimer ceases interim CFO duties and continues as President and CEO.
Xenon Pharmaceuticals appointed Thomas (Tucker) Kelly as Chief Financial Officer, effective October 15, 2025. He becomes the company’s principal financial and accounting officer, bringing prior CFO experience from Deciphera Pharmaceuticals and earlier leadership roles across life sciences finance and banking. Ian Mortimer will cease serving as interim CFO and continues as President and CEO.
Kelly’s employment terms include a $540,000 annual base salary, an annual incentive opportunity up to 45% of base salary, a one-time grant of 225,000 stock options, and 30,000 RSUs under the 2025 Inducement Plan. If terminated without cause outside a change of control period, severance equals 12 months of base salary plus one month per year of service (capped at 18 months), pro‑rated Average Bonus, retirement contributions for the severance period, and limited continued vesting and exercisability. During a change of control period, severance includes 100% target bonus, full vesting acceleration, and extended exercisability as outlined.
Xenon Pharmaceuticals insider transactions by Ian Mortimer show the reporting person exercised a fully vested option to buy 25,000 common shares at $7.69 and simultaneously sold 25,000 shares under a prearranged Rule 10b5-1 plan on 10/01/2025. The sale proceeds reflect an aggregate weighted-average price of $40.16 per share (individual sales ranged $40.00 to $40.495). After these transactions Mortimer directly beneficially owned 31,302 shares and indirectly owned 14,300 shares through his spouse, totaling 45,602 shares. The filing states the option exercised is fully vested and exercisable and that the sales were executed under a 10b5-1 plan.
Xenon Pharmaceuticals (XENE) filed a Form 144 reporting a proposed sale of 25,000 common shares through Canaccord Genuity Corp. on the NASDAQ with an aggregate market value of $1,004,117. The filer states the shares were acquired and paid for on 10/01/2025 by exercising options issued by the company and paid in cash. The notice lists 77,105,799 shares outstanding and reports no securities sold by the filer in the past three months. Some standard filer identification fields (CIK/Contact) are blank in the provided text.
Xenon Pharmaceuticals Inc. (XENE) filed a Form 144 notice reporting a proposed sale of 2,548 common shares through Morgan Stanley Wealth Management Canada Inc. on the NASDAQ with an aggregate market value of $94,490. The shares were acquired on 09/19/2025 by exercise of options from the issuer and were paid via a net exercise on the same date. The filing shows 77,105,799 shares outstanding and reports no securities sold in the past three months by the selling person. The notice includes the standard representation that the seller is not aware of undisclosed material adverse information about the issuer.
Xenon Pharmaceuticals (XENE) received a Schedule 13G/A disclosing that Wellington-affiliated filers report beneficial ownership of 2,174,761 common shares, representing 2.83% of the class. The filing shows no sole voting or dispositive power and shared voting power of 2,146,462, with shared dispositive power of 2,174,761, indicating the positions are managed jointly by Wellington entities.
The filing states these securities are owned of record by Wellington clients and held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer. No client is identified as owning more than 5% of the class.
FAQ
What is the current stock price of Xenon Pharmaceut (XENE)?
What is the market cap of Xenon Pharmaceut (XENE)?
